why not use dpp4 and glp 1 together DPP-4 Inhibitors (Gliptins): Mechanism, Pharmacokinetics, Side Effects & Interactions GLP-1 Receptor Agonists | New

Longer term, Novos expanding pipeline , including late-stage GLP-1 trials targeting Alzheimers and other metabolic disorders, provides asymmetric upside , where success could be transformative but failure carries limited structural downside

While oral antidiabetics and lipid-lowering agents offer potential therapeutic benefits for vitiligo by modulating oxidative stress and inflammation, their use presents limitations ( In conclusion, drug repurposing appears to be an interesting option for vitiligo patients, especially with regards to therapies already approved and prescribed for metabolic disturbances

I would highly recommend to anyone with PCOS

Medication adherence also plays a critical role

Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing